Why did MBIO plummet?

The stock price of MBIO has experienced a significant drop on July 1, 2025, which can be attributed to the following factors:

1. Recent Performance: Mustang Bio's stock has been volatile, with a significant increase of 114.64% on July 1, 2025, followed by a decline of 20.48% in the post-market session. This volatility could be due to market reactions to recent news or earnings reports.
2. Clinical Trial Data: The company's stock saw a significant boost on April 23, 2025, after announcing promising data from their latest clinical trials. However, the recent decline might reflect a correction after the initial excitement wore off.
3. Financial Position: Mustang Bio's financial position has been challenging, with a loss of $951,000 indicated by the EBIT and a cash position of $6,839,000. The company has been expending $664,000 on research and development, which could be a factor in the market's perception of its financial health and future prospects.

In conclusion, the decline in MBIO's stock price can be attributed to a combination of factors including its volatile performance, market correction after initial excitement about clinical trial data, and its challenging financial position.